Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kiora Pharmaceuticals, Inc. (KPRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1625-0.0195 (-10.71%)
At close: 04:00PM EDT
0.1605 -0.00 (-1.23%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.1820
Open0.1992
Bid0.1615 x 3100
Ask0.1625 x 1200
Day's Range0.1600 - 0.2031
52 Week Range0.1400 - 2.3400
Volume34,574,055
Avg. Volume2,071,741
Market Cap5.974M
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-1.7740
Earnings DateAug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KPRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kiora Pharmaceuticals, Inc.
    Analyst Report: Bausch Health Companies Inc.Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Newsfile

    Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results

    Salt Lake City, Utah--(Newsfile Corp. - August 12, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is reporting financial results for the three and six months ended June 30, 2022."In the first half, we continued to advance three core programs toward their next phase of clinical development," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "With the recent financing, we are now in a position to ...

  • Newsfile

    Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics

    Salt Lake City, Utah--(Newsfile Corp. - July 28, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has been granted a U.S. patent covering hydrogel-based sustained release platforms, inclusive of KIO-201, which enable controlled release of antibiotics for the treatment of ocular diseases. The intellectual property, US Patent No. 11,376,214, relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and have poten

  • Newsfile

    Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

    Salt Lake City, Utah--(Newsfile Corp. - July 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.0 million, which includes full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses.The offering was comprised of (i) 23,695,697 shares of common s

Advertisement
Advertisement